By Application
Hot products 
-
Mouse Anti-CCDC6 Recombinant Antibody (CBXC-0106) (CBMAB-C5397-CQ)
-
Mouse Anti-CD24 Recombinant Antibody (SN3) (CBMAB-C1037-CQ)
-
Mouse Anti-CIITA Recombinant Antibody (CBLC160-LY) (CBMAB-C10987-LY)
-
Mouse Anti-ADGRL2 Recombinant Antibody (V2-58519) (CBMAB-L0166-YJ)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503417) (CBMAB-V208-1369-FY)
-
Mouse Anti-AKR1B1 Antibody (V2-2449) (CBMAB-1001CQ)
-
Rat Anti-FABP3 Recombinant Antibody (CBXF-2299) (CBMAB-F1612-CQ)
-
Mouse Anti-BSN Recombinant Antibody (219E1) (CBMAB-1228-CN)
-
Mouse Anti-AKT1 (Phosphorylated S473) Recombinant Antibody (V2-505430) (PTM-CBMAB-0067LY)
-
Mouse Anti-AOC3 Recombinant Antibody (CBYY-0014) (CBMAB-0014-YY)
-
Rabbit Anti-Acetyl-Histone H3 (Lys36) Recombinant Antibody (V2-623395) (CBMAB-CP0994-LY)
-
Mouse Anti-GFAP Recombinant Antibody (24) (CBMAB-G2927-LY)
-
Rabbit Anti-CAMK2A Recombinant Antibody (BA0032) (CBMAB-0137CQ)
-
Mouse Anti-FLI1 Recombinant Antibody (CBXF-0733) (CBMAB-F0435-CQ)
-
Mouse Anti-DLL4 Recombinant Antibody (D1090) (CBMAB-D1090-YC)
-
Mouse Anti-EMP3 Recombinant Antibody (CBFYE-0100) (CBMAB-E0207-FY)
-
Mouse Anti-FeLV g27 Recombinant Antibody (1) (CBMAB-V208-1714-FY)
-
Mouse Anti-CCS Recombinant Antibody (CBFYC-1093) (CBMAB-C1150-FY)
-
Rabbit Anti-CCL5 Recombinant Antibody (R0437) (CBMAB-R0437-CN)
-
Mouse Anti-AQP2 Recombinant Antibody (G-3) (CBMAB-A3359-YC)
Endometrial Cancer
Fig.1 Endometrial cancer
Endometrial cancer is a cancer originating from the endometrium, which is the lining of the womb and uterus. The first sign is most abnormal vaginal bleeding but not associated with menstrual periods. Other symptoms include pain with urination, pelvic pain or sexual intercourse. Endometrial cancer occurs overwhelmingly after menopause. About 40% of cases are related to obesity. Besides it is also associated with diabetes, excessive estrogen exposure and high blood pressure. Hereditary causes contribution to 2–10% of the endometrial cancer cases. The most common type of endometrial cancer is endometrioid carcinoma, which making up more than 80% of cases. The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is around 80%. Prognostic markers, like Serum HE4 have been studied recently.
Loading...


